List of works - E Anders Kolb

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

scientific article published on 18 December 2018

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

scientific article

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

scientific article published on 29 April 2011

Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway

scientific article

Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium

scientific article published on 24 July 2020

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

scientific article published on 30 March 2011

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

scientific article published on 5 August 2016

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

scientific article published on 01 November 2019

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

scientific article published on 30 May 2016

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

scientific article

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

scientific article

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

scientific article

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.

scientific article published on 09 September 2013

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

scientific article published on 16 August 2011

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article published on 18 November 2014

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

scientific article published on 16 June 2011

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

scientific article published on 2 November 2011

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

scientific article published on June 2008

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

scientific article published on October 2009

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

scientific article published on February 2010

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

scientific article published on June 2008

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

scientific article published on 27 September 2014

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

scientific article published on 7 July 2015

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

scientific article published on 21 September 2016

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

scientific article published on December 2009

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

scientific article published on December 2010

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

scientific article published on January 2008

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).

scientific article

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

scientific article published on September 2009

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

scientific article published on 15 September 2011

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

scientific article published on 27 October 2016

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

scientific article

Initial testing of aplidin by the pediatric pre-clinical testing program.

scientific article published on September 2009

Initial testing of cisplatin by the pediatric preclinical testing program

scientific article published on May 2008

Initial testing of dasatinib by the pediatric preclinical testing program

scientific article

Initial testing of lenalidomide by the pediatric preclinical testing program

scientific article published on 25 February 2011

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

scientific article

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

scientific article

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

scientific article published on March 2008

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

scientific article

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

scientific article

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

scientific article published on 19 October 2011

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

scientific article

Initial testing of topotecan by the pediatric preclinical testing program.

scientific article

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma

scientific article

Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.

scientific article published in September 2003

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

scientific article

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

scientific article

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

scientific article published on 23 January 2020

R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

scientific article

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

scientific article published on July 2008

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

scientific article

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

scientific article

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.

scientific article published on 25 August 2015

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

scientific article published on 18 November 2011

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

scientific article

The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate

scientific article published on May 2007

The pediatric preclinical testing program: description of models and early testing results.

scientific article published in December 2007

List of works by E Anders Kolb

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway

Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

Initial testing of aplidin by the pediatric pre-clinical testing program.

Initial testing of cisplatin by the pediatric preclinical testing program

Initial testing of dasatinib by the pediatric preclinical testing program

Initial testing of lenalidomide by the pediatric preclinical testing program

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

Initial testing of topotecan by the pediatric preclinical testing program.

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma

Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate

The pediatric preclinical testing program: description of models and early testing results.